Glomerular disease related to anti-VEGF therapy.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Kidney International

• Publication date

  2008-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/ki.2008.256PMID 18547991
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

  2007cited by this paper
• Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.

  2007cited by this paper
• VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.

  2007cited by this paper
• Role of the VEGF-A Signaling Pathway in the Glomerulus: Evidence for Crosstalk between Components of the Glomerular Filtration Barrier

  2007cited by this paper
• Nephrotic syndrome after bevacizumab: case report and literature review.

  2007cited by this paper
• Thrombotic microangiopathy and anti-VEGF agents.

  2007cited by this paper
• Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma

  2007cited by this paper
• Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.

  2007cited by this paper
• Sickle cell disease, nephrotic syndrome, and renal failure.

  2006cited by this paper
• Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

  2005cited by this paper
• Managing Patients Treated with Bevacizumab Combination Therapy

  2005cited by this paper
• Circulating angiogenic factors and the risk of preeclampsia.

  2004cited by this paper
• Vascular endothelial growth factor165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat anti-glomerular basement membrane glomerulonephritis.

  2004cited by this paper
• The role of vascular endothelial growth factor (VEGF) in renal pathophysiology.

  2004cited by this paper
• Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

  2004cited by this paper
• Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases.

  2003cited by this paper
• A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

  2003cited by this paper
• Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.

  2001cited by this paper
• Collapsing glomerulopathy in renal allografts: a morphological pattern with diverse clinicopathologic associations.

  1999cited by this paper

• Unmasking Renal Complications of Immunotherapy: A Case of Nivolumab-induced FSGS

  2025cites this paper
• Clinicopathological features of kidney injury in patients receiving immune checkpoint inhibitors (ICPi) combined with anti-vascular endothelial growth factor (anti-VEGF) therapy

  2024cites this paper
• A Case of Recurrent Ovarian Cancer with Renal Dysfunction Associated with the Use of Olaparib

  2023influential citation
• Bevacizumab-Induced Nephropathy Presenting as Crescentic Glomerulopathy

  2023cites this paper
• Renal Implications of Long-Term Systemic Bevacizumab for Recurrent Respiratory Papillomatosis

  2023cites this paper
• Nephrotoxicity From Molecularly Targeted Chemotherapeutic Agents.

  2021cites this paper
• Sodium-glucose co-transporter 2 inhibitors and diabetic retinopathy: insights into preservation of sight and looking beyond

  2020cites this paper
• Severe proteinuria during the administration of bevacizumab plus mFOLFOX6 in a colorectal cancer patient after kidney transplantation: a case report

  2020cites this paper
• Phase I Oncology Drug Development

  2020cites this paper
• Pharmacokinetic Considerations for Organ Dysfunction Clinical Trials in Early Drug Development

  2020cites this paper
• Bevacizumab-induced immunoglobulin A vasculitis with nephritis

  2019cites this paper
• Incidence and characteristics of chronic renal replacement therapy in patients with cancer: data from kidney and cancer registries in Basse-Normandie

  2018cites this paper
• A case of focal segmental glomerulosclerosis inferred by bevacizumab

  2018cites this paper
• Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report

  2018cites this paper
• Characteristic morphological changes in anti‐VEGF therapy‐induced glomerular microangiopathy

  2018cites this paper
• Cancer drugs and the glomerulus

  2018cites this paper
• Effect of caffeic acid phenethyl ester (CAPE) on vascular endothelial growth factor a (VEGF-A) gene expression in gentamicin-induced acute renal nephrotoxicity -

  2018cites this paper
• IgA-Dominant Glomerulopathy and Thrombotic Microangiopathy After Chemotherapy

  2017cites this paper
• BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome.

  2017cites this paper
• Antineoplastic agents and thrombotic microangiopathy

  2017cites this paper
• Daily Optical Coherence Tomography Examinations after First Antivascular Endothelial Growth Factor Injections: An Interventional Case Series

  2016cites this paper
• ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy.

  2016cites this paper
• Mechanisms of Hypertension and Renal Injury During Vascular Endothelial Growth Factor Signaling Inhibition

  2016cites this paper
• Collapsing glomerulopathy is common in the setting of thrombotic microangiopathy of the native kidney.

  2016cites this paper
• the setting of thrombotic microangiopathy Collapsing glomerulopathy is common in of the native kidney

  2016cites this paper
• Nephrotoxins and Pediatric Kidney Injury

  2014cites this paper
• All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study.

  2014cites this paper
• New insights into molecular mechanisms of diabetic kidney disease.

  2014cites this paper
• Effects of a Single Intravitreal Injection of Aflibercept and Ranibizumab on Glomeruli of Monkeys

  2014cites this paper
• Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.

  2014cites this paper
• Morphological spectrum of renal pathology and its correlation to clinical features in patients with disseminated intravascular coagulation: A study involving a series of 21 autopsy cases

  2014cites this paper
• [Renal toxicity of anti-VEGF (corrected) targeted therapies].

  2013cites this paper
• A glimpse of the glomerular milieu: from endothelial cell to thrombotic disease in nephrotic syndrome.

  2013cites this paper
• Immunoglobulin A nephropathy with massive paramesangial deposits caused by anti-vascular endothelial growth factor therapy for metastatic rectal cancer: a case report and review of the literature

  2013cites this paper
• Vegfa Protects the Glomerular Microvasculature in Diabetes

  2012cites this paper
• Kidney injury during VEGF inhibitor therapy.

  2012cites this paper
• VEGF Inhibition, Hypertension, and Renal Toxicity

  2012cites this paper
• Exacerbation of diabetic nephropathy mimicking thrombotic microangiopathy during sunitinib treatment for metastatic renal cell carcinoma

  2012cites this paper
• Renal involvement in Castleman disease.

  2011cites this paper
• Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors.

  2011cites this paper
• Role of Vascular Endothelial Growth Factor-A in Diabetic Kidney Disease

  2011cites this paper
• [Nephropathy following administration of angiogenesis inhibitors].

  2011cites this paper
• Title: Thrombotic Microangiopathy with Targeted Cancer Agents

  2011cites this paper
• Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration.

  2011cites this paper
• Thrombotic Microangiopathy with Targeted Cancer Agents

  2011cites this paper
• Biology of anti-angiogenic therapy-induced thrombotic microangiopathy.

  2010cites this paper
• Inhibition of capillary repair in proliferative glomerulonephritis results in persistent glomerular inflammation with glomerular sclerosis

  2010cites this paper
• Bevacizumab increases risk for severe proteinuria in cancer patients.

  2010cites this paper
• VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.

  2010cites this paper
• Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMA

  2010cites this paper
• Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy.

  2010cites this paper
• Chemotherapy-associated renal dysfunction

  2009cites this paper
• Effects of increased renal tubular vascular endothelial growth factor (VEGF) on fibrosis, cyst formation, and glomerular disease.

  2009cites this paper
• Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma

  2009cites this paper
• Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma.

  2009cites this paper
• Sunitinib-aggravated hypertension.

  2009cites this paper
• Renal Complications in Oncohematologic Patients

  2009cites this paper
• Cardiovascular implications of proteinuria: an indicator of chronic kidney disease

  2009cites this paper